<DOC>
	<DOCNO>NCT02278133</DOCNO>
	<brief_summary>The purpose study assess safety anti-tumor activity triple combination WNT974 , LGX818 cetuximab BRAFV600-mutant mCRC RNF43 mutation RSPO fusion . The design study base upon translational pre-clinical data suggest Wnt pathway signal , increase due RNF43 mutation RSPO fusion , cooperate EGFR BRAF signal maintain growth BRAFV600 CRCs . Inhibition signal triple combination WNT974 , LGX818 cetuximab may result anti-tumor activity .</brief_summary>
	<brief_title>Study WNT974 Combination With LGX818 Cetuximab Patients With BRAF-mutant Metastatic Colorectal Cancer ( mCRC ) Wnt Pathway Mutations</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Male female age ≥ 18 year Histological cytological confirm metastatic colorectal cancer Written documentation KRAS wildtype status BRAFV600mutation RNF43 mutation and/or RSPO fusion Progression disease least one prior standard care regimen intolerant irinotecan base regimen Availability representative tumor specimen ( primary metastatic , archival newly obtain ) Measurable disease per RECIST v1.1 Eastern cooperative oncology group ( ECOG ) performance status ≤ 2 Phase II : Prior treatment RAF inhibitor , Wnt pathway inhibitor , cetuximab , panitumumab , and/or EGFR inhibitor Symptomatic brain metastasis . Patients previously treat untreated condition asymptomatic absence corticosteroid antiepileptic therapy allow enroll Current treatment medication consume food strong inhibitor inducer CYP3A4/5 herbal medication discontinue least one week prior start treatment . Symptomatic untreated leptomeningeal disease Acute chronic pancreatitis Clinically significant cardiac disease Patients follow laboratory value Screening/baseline Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 Platelets &lt; 100,000/mm3 Hemoglobin &lt; 9.0 g/dL Serum creatinine &gt; 1.5 x ULN calculate directly measure CrCl &lt; 50 % low limit normal Serum total bilirubin &gt; 1.5 x ULN AST/SGOT and/or ALT/SGPT &gt; 2.5 x ULN , ( &gt; 5 x ULN liver metastasis present ) Patients impaired hepatic function define ChildsPugh class B C Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral WNT974/LGX818 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic ,</keyword>
	<keyword>Colorectal cancer ,</keyword>
	<keyword>WNT974 ,</keyword>
	<keyword>LGX818 ,</keyword>
	<keyword>cetuximab ,</keyword>
	<keyword>BRAF-mutant ,</keyword>
	<keyword>mCRC ,</keyword>
	<keyword>BRAFV600-mutant ,</keyword>
	<keyword>KRAS</keyword>
</DOC>